Leadership and advisors

Chairman of the board since 2026.

‍

Born 1975.

‍

Niklas Frisk is an investor and entrepreneur with board assignments in VPUS Joyous Group and OhMungood AB, among others. Niklas has previously been Senior Vice President of Oriflame where he as a member of Group Management was first responsible for Asia and then Africa and Europe during the period 2012–2020. Prior to that, Niklas worked for 17 years at Alcro-Beckers AB, of which the final seven years as CEO when the company was also listed on Nasdaq Helsinki. He has also been Chairman of the Board of SVEFF – Sveriges Förenade Färgfabrikanter, Chairman of the Board of the Färgglädje Group and also Chairman of the Board of IDSA India. Niklas holds an economics degree and an MBA from the Stockholm School of Economics and the University of Virginia.

‍

Independent in relation to the company and major shareholders.

Board member since 2015.

‍

Born 1964.

‍

Owe is Senior Group Leader at the Karolinska Institute. After completing a PhD in chemistry from Gothenburg University, he completed two years of postdoctoral studies at Stanford University.
Former Global VP of R&D at Sanofi, former President of R&D at Piramal Healthcare, entrepreneur/founder and inventor of six biotech companies, Owe has over 20 years of experience in the pharma and biotech industry. Holder of more than 75 patents, author of hundreds of research articles, he is a pioneer in the fields of single-cell biology and biophysics with several products on the global market.

‍

Dependent in relation to the company / Independent in relation to major shareholders.

Board member since 2026.

‍

Born in 1977.

‍

Karin is Executive Director and Head of Cardiovascular Bioscience within BioPharmaceuticals R&D at AstraZeneca, where she leads strategic and scientific work in cardiovascular research and early drug development. She is a trained pharmacist and has a PhD in oncology from the University of Gothenburg. Karin has a strong scientific background in cardiovascular research, regenerative medicine and advanced cell models, as well as long and broad experience from the pharmaceutical industry. She has held leading roles throughout the drug development chain and is the author of several scientific publications.

‍

Independent in relation to the company and major shareholders.

‍

Board member since 2017.

‍

Born 1972.

‍

Education at Harvard University, Stanford University and UC Berkeley.

‍

Daniel has been Professor of Chemistry and Bioengineering at the University of Washington since 2006. After graduating from Stanford University, he completed postdoctoral research at Harvard University.
Scientific Founder of multiple Life Sciences/Biomedical companies across Asia, Europe, and U.S.A Member/Chair of numerous advisory and review panels for government and industry, he is a pioneer in the field of single-cell biology with several products on the global market. Daniel has authored more than 200 scientific publications and is the inventor on over 60 issued patents.

‍

Independent in relation to the company and major shareholders.

Board member since 2017.

‍

Born in 1975.

‍

Master of Laws, University of Gothenburg.

‍

Carl is an experienced and recognized lawyer at MAQS’ Gothenburg office. He has extensive experience of commercial agreements, including ones relating to cooperation, commission, and purchasing, as well as to terms and conditions. He specializes in sports, media, and the entertainment industry in which he has worked for over ten years, in addition to being the sports director of the football club BK Häcken four years. Considering Carl’s dual legal and managerial background, has led him to assist many boards in an advisory manner, or to join them as a member or a chairman.

‍

Independent in relation to the company and major shareholders.

Board member since 2026.

‍

Born in 1974.

‍

Alex Scheepers is a senior executive with more than 20 years of experience in the pharmaceutical and advanced manufacturing sectors, including over a decade leading large, highly regulated organisations within Recipharm and Octapharma. He brings deep expertise in strategic leadership, financial oversight, operational transformation and governance in complex global environments. Alex has a strong track record of improving performance and executing major transformation programs, while aligning organisations behind clear long-term strategies. With an MBA from the Stockholm School of Economics and executive training from INSEAD, he combines analytical rigour with a pragmatic approach to value creation, with a particular interest in emerging technology and life science innovation.

‍

Independent in relation to the company and major shareholders.

Board member since 2026.

‍

Born in 1978.

‍

Peter Kjäll holds a Ph.D. in Medical Sciences and working at the intersection of digital health, healthtech, and healthcare transformation. His expertise spans medtech, biotech, AI, welfare technology and eHealth, with a strong focus on commercialization, value creation, and implementation. With experience in risk assessment from a venture capital perspective and international matchmaking across academia, industry, and healthcare, he is actively working with enterprise politics and policymaking to create the best conditions for the industry to accelerate the adoption of technological innovations that shape the future of healthcare.

‍

Independent in relation to the company and major shareholders.

‍

‍

Board member since 2026.

‍

Born in 1976.

‍

Kader Abdul holds a Master's degree in Microbiology from the University of Dhaka, an MBA in Marketing from the Institute of Business Administration and a PhD from the Department of Microbiology, Tumor and Cell Biology (MTC) at Karolinska Institutet. Kader has been part of several research groups, including at the Wenner-Gren Center, the Swedish Medical Nanoscience Center and Karolinska Institutet. Kader has been involved in several small and medium-sized companies where he has helped them position themselves in the global market. He has also worked in various roles at several organizations globally and has been particularly interested in the positive impact of products and services. Kader Abdul is co-founder of Viola Vitalis AB and has been the company's CEO since 2010.

‍

Independent in relation to the company and major shareholders.

PhD in cardiovascular physiology and pharmacology from Gothenburg University.‍Regina is Senior Vice President and Head of Research and Early Development, Cardiovascular, Renal and Metabolism at AstraZeneca and leads drug development from target discovery through clinical proof-of-concept in the areas Unmet medical need and Cardiovascular and metabolic diseases. The main focus of the research that Danielson leads is to develop new therapies that can cure disease or stop disease progression, with regenerative approaches and precision medicine as key strategies. Regina is part of the management team for several strategic research collaborations, as well as in the British Heart Foundation Center for Research Excellence (CRE) Cambridge, the Physiological Systems Domain Panel and the Medical Research Council (MRC).​​

Dr. Astrid Brodd is a licensed physician who studied at the University of Toulouse and at the Sahlgrenska Academy of the University of Gothenburg. She is a board-approved dermatologist since 1993 and started the dermatology clinic at the Carlanderska hospital in 1998.

‍

Dr. Astrid Brodd is active at Diagnostiskt Centrum Hud in Gothenburg. She has extensive clinical experience both from work in Sweden and internationally.

Dr. Göran Gannedahl is a licensed physician and Ph.D who studied at the Karolinska Institute and the University of Uppsala. He is a board-approved surgeon.

‍

Dr. Gannedahl has a vast experience of drug development in different therapeutic areas from leading positions in companies such as Novartis and AstraZeneca. He is the Chief Medical Officer at Oblique Therapeutics in Gothenburg.

Prof. Michael Olausson is a licensed physician and Ph.D who studied at the Sahlgrenska Academy of the university of Gothenburg. He is a board-certified specialist in transplantation surgery.

‍

Professor Olausson has been active as a transplantation surgeon at the Sahlgrenska Academy and Sahlgrenska University hospital since 1987. He is the founder and chairman of the Sahlgrenska Transplant Institute and is the author of more than 300 research papers and book chapters. Professor Olausson is a pioneer in the area of transplantation surgery and has introduced and conducted new innovative therapies as first in the world, first in Europe, first in Scandinavia and first in Sweden.